The study highlighted the significance of the PI3K/Akt pathway in glioblastoma by demonstrating reduced motility and EGF stimulating properties in GBM cells treated with wortmannin, a PI3K inhibitor. This evidence concerns the gene AKT1 and glioblastoma.